Compugen Appoints Michele Holcomb to Strengthen AI-Driven Clinical Development and Partnering

New board addition targets development and partnering execution

Compugen appoints Michele Holcomb, Ph.D., as an independent director effective Feb. 11, 2026, in a move the company says is intended to sharpen its ability to move computationally discovered programs through clinical development and commercial partnerships. The Holon, Israel-based clinical-stage cancer immunotherapy company highlights her more than three decades of experience in biotech, pharmaceuticals and healthcare services, and says her strategic and operational expertise will support conversion of discovery assets into clinical and commercial value.

Board chair Anat Cohen-Dayag says Holcomb’s background in strategy, business development and R&D operations fits Compugen’s current priorities, which include advancing multiple potential first-in-class clinical programs and leveraging two validating pharmaceutical partnerships. Compugen stresses that its AI/ML-powered computational discovery engine generates differentiated candidates, and the company expects Holcomb to strengthen the board’s capacity to accelerate timelines, optimize portfolios and facilitate partnering decisions as those programs move through clinical milestones.

Holcomb, who joins from senior roles at Cardinal Health and Teva Pharmaceuticals, is presented as a hands-on operator with experience leading investments, acquisitions, integrations and portfolio optimization. She comments that she is honored to join a company that repeatedly generates and advances differentiated cancer programs and that Compugen’s blend of scientific innovation, strategic focus and disciplined partnering provides a compelling platform for sustained value creation. The appointment is framed as part of Compugen’s broader effort to bolster governance and corporate development resources in support of late preclinical and clinical-stage execution.

Company position and strategic context

Compugen is a clinical-stage cancer immunotherapy company and pioneer in AI/ML-powered computational drug target discovery. The firm enters 2026 emphasizing its computational discovery engine, multiple clinical-stage programs and existing pharmaceutical collaborations as the pillars for advancing novel immuno-oncology candidates.

Holcomb’s professional profile

Holcomb brings executive experience including EVP and Chief Strategy and Business Development Officer at Cardinal Health and senior R&D and strategy roles at Teva where she oversaw pipeline asset evaluation for licensing. Compugen notes her public and private board service and operational track record as key assets for guiding the company through partnership negotiations, program prioritization and integration activities.